Low Disease Activity and Drug-Free Remission in Anti- MDA5 Dermatomyositis
JAMA Dermatology · 18.11.2026
DOI: 10.1001/jamadermatol.2026.4776 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, online erschienen am 18.11.2026. Verfasst von Xiaoqin Luo und 27 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Importance Anti–melanoma differentiation–associated gene 5 ( MDA5 )–positive dermatomyositis ( MDA5 -DM) is associated with rapid progression and high early mortality, but long-term outcomes beyond the early high-risk phase remain poorly characterized.
Objective
To evaluate the attainability, associated factors, and durability of low disease activity (LDA) and drug-free remission (DFR) in patients with MDA5 -DM. Design, Setting, and Participants This retrospective cohort study at a tertiary referral center in China included consecutive patients with MDA5 -DM who were enrolled between August 2003 and July 2023 and followed up through August 2025. Median follow-up was 5.7 (IQR, 3.4-7.4) years. The data were analyzed from September 2025 through December 2025. Exposures Baseline demographic, clinical, and laboratory characteristics. Main Outcomes and Measures Primary outcomes were experiencing LDA and DFR. Secondary outcomes included relapse after LDA or DFR and patient-reported outcomes assessed using the Patient Global Assessment and Health Assessment Questionnaire Disability Index.
Results
Of 561 screened patients, 523 (93.2%) were included. Among 523 patients with MDA5 -DM, 345 (65.9%) were female, 178 (34.1%) were male, and the median age at disease onset was 50.0 years (IQR, 41.0-57.5 years). Interstitial lung disease was present in 488 patients (93.3%) at baseline. Cumulative 1-, 3-, 5-, and 10-year all-cause mortality was 28.1%, 30.5%, 30.8%, and 31.7%, respectively. The 1-, 3-, 5-, and 10-year cumulative incidences of LDA were 3.1%, 47.1%, 59.0%, and 66.8%, respectively; corresponding incidences of DFR were 0%, 5.0%, 15.1%, and 31.0%, respectively. The median time from enrollment was 23 months (IQR, 18-34) for LDA and 46 months (IQR, 37-67) for DFR. Respiratory failure was associated with lower rates of LDA (subdistribution hazard ratio [sHR], 0.31; 95% CI, 0.19-0.51) and DFR (sHR, 0.33; 95% CI, 0.12-0.87), whereas a higher CD8-positive T-cell count was associated with higher rates of LDA (sHR, 1.15; 95% CI, 1.08-1.22) and DFR (sHR, 1.19; 95% CI, 1.09-1.31). The 5-year relapse-free probabilities were 76.7% after LDA and 82.0% after DFR. LDA and DFR were associated with lower Patient Global Assessment and Health Assessment Questionnaire Disability Index scores compared with non-LDA or non-DFR states. Conclusions and Relevance The findings of this cohort study suggest that LDA was an attainable and durable long-term outcome for many patients with MDA5 -DM, whereas DFR occurred less frequently. These findings may inform long-term disease control targets and treatment expectations in MDA5 -DM.
Zitieren
APA
Luo, X., Zong, C., Ji, H., Li, S., Chen, Y., Zhu, L., Zhang, X., Dai, Y., Luo, L., Li, Y., Pan, Q., Xiao, X., Jiang, W., Ge, Y., He, L., Chen, F., Li, C., Liang, L., Li, S., …, & Peng, Q. (2026). Low Disease Activity and Drug-Free Remission in Anti- MDA5 Dermatomyositis. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2026.4776
Vancouver
Luo X, Zong C, Ji H, Li S, Chen Y, Zhu L, et al. Low Disease Activity and Drug-Free Remission in Anti- MDA5 Dermatomyositis. JAMA Dermatology. 2026. doi:10.1001/jamadermatol.2026.4776
BibTeX
@article{Luo2026,
author = {Luo, Xiaoqin and Zong, Chen and Ji, Huihui and Li, Shanshan and Chen, Yiran and Zhu, Longyang and Zhang, Xinxin and Dai, Yunfeng and Luo, Lin and Li, Ying and Pan, Qi and Xiao, Xinyue and Jiang, Wei and Ge, Yongpeng and He, Linrong and Chen, Fang and Li, Chunjia and Liang, Lin and Li, Shanshan and Li, Sizhao and Liu, Xia and Tian, Xiaolan and Yang, Hanbo and Zhang, Lu and Shu, Xiaoming and Lu, Xin and Wang, Guochun and Peng, Qinglin},
title = {Low Disease Activity and Drug-Free Remission in Anti- MDA5 Dermatomyositis},
journal = {JAMA Dermatology},
year = {2026},
doi = {10.1001/jamadermatol.2026.4776}
}
EUVIMED